Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology

Treatment Options for Bone Marrow Failure

At a Glance

Treatment for dyskeratosis congenita-related bone marrow failure is individualized and may include transfusions and other supportive care, androgen medicines, or an allogeneic stem cell transplant. Transplant can restore blood production but does not prevent DC-related lung, liver, or cancer risks.

When Dyskeratosis Congenita (DC) leads to bone marrow failure, the goal of treatment is to manage low blood counts and restore health. Because DC is a multisystem disorder, treatment decisions are complex and must be managed by a specialized care team [1][2]. Treatment paths generally involve observation and supportive care, medication (androgens), or a bone marrow transplant [3][2]. Note that you should not choose between these options based on a guide; these are individualized decisions made with a specialist.

Supportive Care

Before considering aggressive interventions, many patients rely on vital supportive measures. This includes blood transfusions to treat symptomatic anemia or bleeding risks, medications to prevent or treat infections due to low white blood cells, and therapies to manage the iron overload that can occur from repeated blood transfusions [4].

Androgen Therapy: A Medication Option

For some patients, androgens (synthetic hormones like danazol or oxymetholone) are an option to stimulate the bone marrow to produce more red blood cells and platelets [3][5].

  • Variable Response: While androgens can improve blood counts in some patients, responses in DC are variable and can be temporary [3].
  • Significant Risks: Long-term use requires rigorous monitoring. Androgens can cause cholestatic liver injury, peliosis hepatis (blood-filled cysts in the liver), hepatic adenomas, and an increased risk of thrombosis (blood clots). They also negatively impact cholesterol levels, raising cardiovascular risk [6][7].
  • Physical Changes: These drugs can cause virilization—potentially irreversible changes like acne, increased body hair, or deepening of the voice, alongside mood or reproductive effects [3][6].
  • Limitations: Androgens do not cure the underlying genetic defect, and patients must still be closely monitored for progression to leukemia or other cancers [8].

Hematopoietic Stem Cell Transplant (HSCT)

An allogeneic hematopoietic stem cell transplant (HSCT) is a major procedure that replaces your failing bone marrow with healthy stem cells from a donor [2].

What HSCT Can and Cannot Do

It is vital to understand the scope of a transplant [1].

  • The Benefit: It is potentially curative for the hematologic (blood) manifestations of the disease, resolving marrow failure and reducing the immediate risk of blood cancers like MDS/AML [1].
  • The Major Risks: HSCT carries substantial life-threatening risks, including graft failure, graft-versus-host disease (GVHD), severe infection, organ toxicity, infertility, and secondary malignancies [1].
  • The Limitation: It does not fix or stop the progression of DC in other organs [1][9]. Even after a successful transplant, patients remain at risk for lung scarring, liver disease, and solid tumors [10][11].

Specialized “Reduced-Intensity” Protocols

Because patients with DC are highly sensitive to DNA-damaging treatments, specialized transplant centers individualize conditioning regimens [2]. These reduced-intensity conditioning (RIC) protocols (often incorporating drugs like fludarabine) aim to minimize radiation and toxic chemotherapy to reduce the risk of life-threatening lung and liver damage, though they are still serious and not entirely devoid of toxicity [12][13].

The Importance of Donor Screening

Choosing a donor is one of the most critical steps in the transplant process.

  • The “Silent” Risk: Because TBDs can be “cryptic,” a family member who appears healthy might actually have shortened telomeres or the same genetic variant [14][15].
  • Mandatory Testing: All potential related donors must undergo age-adjusted telomere length testing and genetic screening before being cleared [2][16]. Using a donor with short telomeres can cause the transplant to fail [17].

Common questions in this guide

What are the main treatment options for bone marrow failure caused by dyskeratosis congenita?
Treatment is individualized by a specialized care team. Options may include supportive care such as transfusions and infection treatment, androgen medicines such as danazol or oxymetholone, and an allogeneic stem cell transplant from a donor.
Can androgen medicines such as danazol cure dyskeratosis congenita?
No. Androgens may raise red blood cell and platelet counts in some people, but the response can be temporary and these medicines do not correct the inherited cause. Long-term use requires monitoring for liver injury, blood clots, cholesterol changes, and physical changes such as virilization.
Is a bone marrow transplant a cure for dyskeratosis congenita?
A transplant can potentially correct the blood-related effects of dyskeratosis congenita and reduce the immediate risks from marrow failure and blood cancers. It does not stop disease-related problems in other organs, so lung disease, liver disease, and solid tumors may still require long-term monitoring. The transplant itself also carries serious risks.
Why must related stem cell donors be tested for short telomeres?
Some relatives may carry the same genetic change or have unusually short telomeres without obvious symptoms. Age-adjusted telomere testing and genetic screening help identify an unsafe donor, because a donor with short telomeres can increase the risk that the transplant will fail.
What does reduced-intensity conditioning mean in a dyskeratosis congenita transplant?
It is a transplant preparation plan that uses less radiation and less toxic chemotherapy than standard conditioning. Because people with dyskeratosis congenita are especially sensitive to DNA-damaging treatment, specialized centers may use this approach to reduce lung and liver toxicity, but it remains serious and can still cause complications.
What monitoring is needed after a transplant for dyskeratosis congenita bone marrow failure?
Follow-up must continue even if the transplant successfully restores blood-cell production. The care team monitors for complications such as lung scarring, liver disease, infections, graft-versus-host disease, infertility, and later cancers, because the transplant does not correct the underlying telomere disorder in other organs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my (or my child's) bone marrow failure progressing to the point where we need to consider a transplant, or should we discuss supportive care or androgen therapy?
  2. 2.If we use danazol, what is our specific monitoring plan for liver health, blood clots, and cholesterol levels?
  3. 3.How will you screen my family members to ensure a potential donor doesn't have 'silent' short telomeres or the same genetic mutation?
  4. 4.Does this transplant center use a 'reduced-intensity' conditioning regimen tailored for Telomere Biology Disorders?
  5. 5.After a transplant, how will we continue to monitor for lung or liver complications, since the transplant only replaces the blood system?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.

    Fioredda F, Iacobelli S, Korthof ET, et al.

    British journal of haematology 2018; (183(1)):110-118 doi:10.1111/bjh.15495.

    PMID: 29984823
  2. 2

    Stem cell transplantation and gene therapy for telomere biology disorders: Historical perspective, current approaches, and emerging strategies.

    Koo J, Reed HD, Myers KC, Agarwal S

    Seminars in hematology 2025; (62(6)):493-502 doi:10.1053/j.seminhematol.2026.03.001.

    PMID: 41916788
  3. 3

    Treatment of inherited bone marrow failure syndromes beyond transplantation.

    Calado RT, Clé DV

    Hematology. American Society of Hematology. Education Program 2017; (2017(1)):96-101 doi:10.1182/asheducation-2017.1.96.

    PMID: 29222242
  4. 4

    Inherited bone marrow failure syndromes: considerations pre- and posttransplant.

    Alter BP

    Hematology. American Society of Hematology. Education Program 2017; (2017(1)):88-95 doi:10.1182/asheducation-2017.1.88.

    PMID: 29222241
  5. 5

    Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita.

    Kirschner M, Vieri M, Kricheldorf K, et al.

    British journal of haematology 2021; (193(3)):669-673 doi:10.1111/bjh.16997.

    PMID: 32744739
  6. 6

    Effects of nandrolone decanoate on telomere length and clinical outcome in patients with telomeropathies: a prospective trial.

    Clé DV, Catto LFB, Gutierrez-Rodrigues F, et al.

    Haematologica 2023; (108(5)):1300-1312 doi:10.3324/haematol.2022.281808.

    PMID: 36579443
  7. 7

    Lipoprotein particle alterations due to androgen therapy in individuals with dyskeratosis congenita.

    Thompson MB, Muldoon D, de Andrade KC, et al.

    EBioMedicine 2022; (75()):103760 doi:10.1016/j.ebiom.2021.103760.

    PMID: 34929494
  8. 8

    Clonal hematopoiesis in patients with dyskeratosis congenita.

    Perdigones N, Perin JC, Schiano I, et al.

    American journal of hematology 2016; (91(12)):1227-1233 doi:10.1002/ajh.24552.

    PMID: 27622320
  9. 9

    Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

    Hudda Z, Myers KC

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):141-148 doi:10.1182/hematology.2023000471.

    PMID: 38066882
  10. 10

    Analysis of Late Complications Associated With Hematopoietic Stem Cell Transplantation in Patients With Dyskeratosis Congenita.

    Koike T, Yamamoto S, Shibata M, et al.

    Pediatric blood & cancer 2025; (72(8)):e31757 doi:10.1002/pbc.31757.

    PMID: 40356079
  11. 11

    Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes.

    Sakaguchi H, Yoshida N

    International journal of hematology 2022; (116(1)):16-27 doi:10.1007/s12185-022-03362-4.

    PMID: 35633493
  12. 12

    Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.

    Dimitrov M, Merkle S, Cao Q, et al.

    Transplantation and cellular therapy 2024; (30(10)):1005.e1-1005.e17 doi:10.1016/j.jtct.2024.07.007.

    PMID: 39002862
  13. 13

    Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review.

    Bhoopalan SV, Wlodarski M, Reiss U, et al.

    Pediatric blood & cancer 2021; (68(10)):e29177 doi:10.1002/pbc.29177.

    PMID: 34086408
  14. 14

    Clinical manifestations of telomere biology disorders in adults.

    Niewisch MR, Beier F, Savage SA

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):563-572 doi:10.1182/hematology.2023000490.

    PMID: 38066848
  15. 15

    Diagnostic utility of telomere length testing in a hospital-based setting.

    Alder JK, Hanumanthu VS, Strong MA, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2018; (115(10)):E2358-E2365 doi:10.1073/pnas.1720427115.

    PMID: 29463756
  16. 16

    A Proposed Clinical Diagnostic Framework for Short Telomere Syndrome.

    Courtwright A, King RA, Vagher J, et al.

    Clinical genetics 2026; (110(2)):139-149 doi:10.1111/cge.70190.

    PMID: 42219160
  17. 17

    Human length telomeres restrict the regenerative potential of hematopoietic stem cells in mice.

    Rowe M, Tober J, Ortiz V, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.08.26.672314.

    PMID: 40909680

This page is for informational purposes only and does not constitute medical advice. Decisions about dyskeratosis congenita-related bone marrow failure, including androgen therapy or transplant, should be made with a specialized hematology and transplant team.

Get notified when new evidence is published on Dyskeratosis congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.